GW Pharmaceuticals Advances its Pipeline with Schizophrenia Trial Results

GW Pharmaceuticals (NASDAQ: GWPH), at work on treatments derived from cannabis, is planning to expand its focus to schizophrenia after charting some positive signs in an exploratory trial.

The company compared cannabidiol, the active ingredient in its lead drug, with placebo in 88 patients with schizophrenia who didn’t respond to first-line therapy. GW Pharma’s treatment demonstrated a statistically significant improvement on three measures of schizophrenia severity, the company said, adding that “the majority of other endpoints in the study were in favor of (cannabidiol) and approached statistical significance in many cases.”

We believe that the signals of efficacy demonstrated in this trial, together with a notably reassuring safety profile, provide GW with the prospect of new and distinct cannabinoid neuropsychiatric product pipeline opportunity

Justin Gover, CEO of GW Pharma

Read Damian Garde’s “GW sees a future in schizophrenia with its cannabis-based pipeline”: http://www.fiercebiotech.com/story/gw-sees-future-schizophrenia-its-cannabis-based-pipeline/2015-09-15 

Published by NCV Newswire
NCV Newswire
The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. Have a confidential news tip? Get in touch.

Get Our Sunday Newsletter